Eosinophilic granulomatosis with polyangitis:
A new target for biologicals

ÇELEBI SOZENER, ZEYNEP; Bayrak Durmaz, Makbule Seda; Bavbek, Sevim

doi:10.5578/tt.20229911

Eosinophilic granulomatosis with polyangitis: A new target for biologicals

Makbule Seda BAYRAK DURMAZ, (Ankara Üniversitesi Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, İmmünoloji ve Alerji Bilim Dalı, Ankara, Türkiye)

Zeynep ÇELEBİ SÖZENER, (Ankara Üniversitesi Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, İmmünoloji ve Alerji Bilim Dalı, Ankara, Türkiye)

Sevim BAVBEK (Ankara Üniversitesi Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, İmmünoloji ve Alerji Bilim Dalı, Ankara, Türkiye)

Tüberküloz ve Toraks

3 1

Yıl: 2022 Cilt: 70 Sayı: 1 Sayfa Aralığı: 93 - 101 Metin Dili: İngilizce DOI: 10.5578/tt.20229911 İndeks Tarihi: 29-06-2022

Eosinophilic granulomatosis with polyangitis: A new target for biologicals

Öz:

Eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss syndrome) is a rare systemic necrotizing granulomatous vasculitis in the spectrum of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Nevertheless, EGPA has specific clinical, biological and histological properties different from other AAVs [microscopic polyangiitis (MPA) and granulomatous polyangiitis (GPA)]. Recently, thanks to the studies conducted to understand the pathophysiology of EGPA, unlike neutrophils in other AAVs, the main cells involved in EGPA have been observed to be eosinophils. The key role of eosinophils in EGPA and recent development of targeted agents to treat other eosinophil-related diseases have created new therapeutic opportunities for EGPA. Conventional treatment of EGPA relies mainly on agents that decrease inflammation. Cornerstone therapy is systemic glucocorticoids, used as monotherapy or in combination with immunosuppressive agents. However, new therapeutic approaches are needed especially for persistent asthma symptoms, refractory disease, relapses and problems associated with corticosteroid dependence. Recently, the first large-scale randomized controlled clinical trial on polyangiitis and eosinophilic granulomatosis has demonstrated the efficacy of eosinophil-targeted biotherapy anti-interleukin-5 (IL-5) mepolizumab, and is approved for the management of EGPA. This finding opens a new era for EGPA management. This review provides an overview of eosinophilic granulomatosis with polyangiitis in the light of new targeted biological therapies.

Anahtar Kelime:

Eozinofilik granülomatöz polianjitis: Biyolojikler için yeni bir hedef

Öz:

Eozinofilik granülomatöz polianjitis (EGPA, Churg-Strauss sendromu), antinötrofil sitoplazmik antikor (ANCA) ile ilişkili vaskülit (AAV) spektrumunda nadir görülen sistemik nekrotizan granülomatöz vaskülittir. Bununla birlikte, EGPA’nın diğer AAV’lerden [mikroskopik polianjiitis (MPA) ve granülomatöz polianjit (GPA)] farklı olarak spesifik klinik, biyolojik ve histolojik özellikleri vardır. Son zamanlarda; EGPA’nın patofizyolojisini anlamak için yapılan çalışmalar sayesinde EGPA’da görev alan ana hücrelerin diğer AAV’lerdeki görev alan nötrofillerden farklı olarak eozinofiller olduğu gözlemlendi. Eozinofillerin EGPA’daki kilit rolü ve diğer eozinofil ile ilişkili hastalıkları tedavi etmek için hedeflenen ajanların son zamanlardaki gelişimi, EGPA için yeni terapötik fırsatlar yaratmıştır. EGPA’nın geleneksel tedavisi, esas olarak antiinflamatuvar ajanlardır. Başlıca ana tedavisi, monoterapi olarak veya immünosupresif ajanlarla kombinasyon halinde kullanılan sistemik glukokortikoidlerdir. Ancak özellikle persistan astım semptomları, refrakter hastalık, relapslar ve kortikosteroid bağımlılığı ile ilişkili problemler için yeni tedavi yaklaşımlarına ihtiyaç duyulmaktadır. Yakın zamanlı; eozinofilik granülomatöz polianjitis üzerine ilk büyük ölçekli randomize kontrollü klinik çalışma, eozinofil hedefli biyoterapi anti-interlökin- 5 (IL-5) mepolizumabın etkinliğini göstermiştir ve EGPA tedavisi için onaylanmıştır. Bu çalışma sonuçları EGPA tedavisi için yeni bir çağ açmaktadır. Bu derleme, yeni hedefe yönelik biyolojik tedaviler ışığında eozinofilik granülomatozis polianjitise genel bir bakış sunmaktadır.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65(01): 1-11. https://doi.org/10.1002/art.37715
2. Watts RA, Lane SE, Scott DG, Koldingsnes W, Nossent H, Gonzalez Gay MA, et al. Epidemiology of vasculitis in Europe. Ann Rheum Dis 2001; 60: 1156–7. https://doi. org/10.1136/ard.60.12.1156a
3. Vega Villanueva KL, Espinoza LR. Eosinophilic vasculitis. Curr Rheumatol Rep 2020; 22(1) :5. https://doi. org/10.1007/s11926-020-0881-2
4. Raffray L, Guillevin L. Treatment of eosinophilic granulomatosis with polyangiitis: a review. Drugs 2018; 78: 809–21. https://doi.org/10.1007/s40265-018-0920-8
5. Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med 2017; 376(20): 1921-32. https://doi.org/10.1056/ NEJMoa1702079
6. Chaigne B, Terrier B, Thieblemont N, Witko Sarsat V, Mouthon L. Dividing the Janus vasculitis? Pathophysiology of eosinophilic granulomatosis with polyangitis. Autoimmun Rev 2016; 15: 139–45. https://doi. org/10.1016/j.autrev.2015.10.006
7. Vaglio A, Martorana D, Maggiore U, Grasselli C, Zanetti A, Pesci A, et al. Secondary and Primary Vasculitis Study Group. HLA-DRB4 as a genetic risk factor for Churg- Strauss syndrome. Arthritis Rheum 2007; 56(09): 3159– 66. https://doi.org/10.1002/art.22834
8. Smith K. Genetic studies in ANCA-associated vasculitis point to a new, practical disease classification based on autoantibody specificity. The 18th International Vasculitis and ANCA Workshop, Tokyo; 2017.
9. Lyons P, Peters J, Alberici F, Liley J, Coulson RMR, Astle W, et al. Genetically distinct clinical subsets, and associations with asthma and eosinophil abundance, within Eosinophilic Granulomatosis with Polyangiitis. BioRxiv; 2018. https://doi.org/10.1101/491837
10. Nguyen Y, Guillevin L. Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss). Semin Respir Crit Care Med 2018; 39(04): 471–81. https://doi. org/10.1055/s-0038-1669454
11. Hellmich B, Csernok E, Gross WL. Proinflammatory cytokines and autoimmunity in Churg–Strauss syndrome. Ann N Y Acad Sci 2005; 1051: 121131. https://doi. org/10.1196/annals.1361.053
12. Marvisi C, Sinico RA, Salvarani C, Jayne D, Prisco D, Terrier B, et al. New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group. Intern Emerg Med 2019; 14(8): 1193-7. https://doi.org/10.1007/s11739- 019-02166-5
13. Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33: 1094e100. https://doi.org/10.1002/ art.1780330806
14. Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984; 63: 65–81. https://doi. org/10.1097/00005792-198403000-00001
15. Robson J, Grayson P, Ponte C, Suppiah R, Craven A, Khalid S, et al. Classificatıon criteria for the anca-associated vasculitides. Rheumatology (Oxford) 2019; 58: (Supplement_2) kez058.050. https://doi.org/10.1093/ rheumatology/kez058.050
16. Saku A, Furuta S, Hiraguri M, Ikeda K, Kobayashi Y, Kagami SI, et al. Long-term outcomes of 188 Japanese patients with eosinophilic granulomatosis with polyangiitis. J Rheumatol 2018 ;45: 1159e66. https://doi.org/10.3899/ jrheum.171352
17. Durel CA, Berthiller J, Caboni S, Jayne D, Ninet J, Hot A. Long-term follow-up of a multicentre cohort of 101 patients with eosinophilic granulomatosis with polyangiitis (EGPA). Arthritis Care Res 2016; 68: 374e87. https:// doi.org/10.1002/acr.22686
18. Comarmond C, Pagnoux C, Khellaf M, Cordier JF, Hamidou M, Viallard JF, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French vasculitis study group cohort. Arthritis Rheum 2013; 65: 270e81. https://doi.org/10.1002/art.37721
19. Sinico RA, Di Toma L, Maggiore U, Bottero P, Radice A, Tosoni C, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005; 52: 2926e35. https:// doi.org/10.1002/art.21250
20. Sablé Fourtassou R, Cohen P, Mahr A, Pagnoux C. Antineutrophil cytoplasmic antibodies and the Churg- Strauss syndrome. Ann Intern Med 2005; 143:632. https://doi.org/10.7326/0003-4819-143-9-200511010- 00006
21. Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Toumelin PL. French Vasculitis Study Group (FVSG). The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011; 90(1): 19-27. https://doi.org/10.1097/ MD.0b013e318205a4c6
22. U.S. Food and Drug Administration. Prescribing information for Nucala (mepolizumab). Available from: https:// www. a c c e s s d a t a . f d a . g ov / d r u g s a t f d a _ d o c s / label/2017/125526s004lbl.pdf (Access date: December 27, 2017).
23. Yanagibashi T, Satoh M, Nagai Y, Koike M, Takatsu K. Allergic diseases: from bench to clinic-contribution of the discovery of interleukin-5. Cytokine 2017; 98: 59-70. https://doi.org/10.1016/j.cyto.2016.11.011
24. Keating GM. Mepolizumab: first global approval. Drugs 2015; 75: 2163-9. https://doi.org/10.1007/s40265-015- 0513-8
25. Jakiela B, Szczeklik W, Plutecka H, Sokolowska B, Mastalerz L, Sanak M, et al. Increased production of IL-5 and dominant Th2-type response in airways of Churg– Strauss syndrome patients. Rheumatology (Oxford) 2012; 51: 1887-93. https://doi.org/10.1093/rheumatology/ kes171
26. Kahn JE, Grandpeix Guyodo C, Marroun I, Catherinot E, Mellot F, Roufosse F, et al. Sustained response to mepolizumab in refractory Churg-Strauss syndrome. J Allergy Clin Immunol 2010; 125(1):267-70. https://doi. org/10.1016/j.jaci.2009.10.014
27. Kim S, Marigowda G, Oren E, Israel E, Wechsler ME. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 2010; 125(6): 1336-43. https://doi. org/10.1016/j.jaci.2010.03.028
28. Moosig F, Gross WL, Herrmann K, Bremer JP, Hellmich B. Targeting Interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med 2011; 155(5): 341. https://doi.org/10.7326/0003-4819-155-5- 201109060-00026
29. Steinfeld J, Bradford ES, Brown J, Mallett S, Yancey SW, Akuthota P, et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 2019; 143(6): 2170-7. https://doi.org/10.1016/j. jaci.2018.11.041
30. Vultaggio A, Nencini F, Bormioli S, Vivarelli E, Dies L, Rossi O, et al. Low-dose mepolizumab effectiveness in patients suffering from eosinophilic granulomatosis with polyangiitis. Allergy Asthma Immunol Res 2020; 12(5): 885-93. https://doi.org/10.4168/aair.2020.12.5.885
31. Padoan R, Chieco Bianchi F, Marchi MR, Cazzador D, Felicetti M, Emanuelli E, et a. Benralizumab as a glucocorticoid- sparing treatment option for severe asthma in eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract 2020; 8(9): 3225-3227.e2. https://doi. org/10.1016/j.jaip.2020.05.033
32. Guntur VP, Manka LA, Denson JL, Dunn RM, Dollin YT, Gill M, et al. Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract 2021; 9(3): 1186-93. https:// doi.org/10.1016/j.jaip.2020.09.054
33. Takenaka K, Minami T, Yoshihashi Y, Hirata S, Kimura Y, Kono H. Decrease in MPO-ANCA after administration of benralizumab in eosinophilic granulomatosis with polyangiitis. Allergol Int 2019; 68(4): 539-40. https://doi. org/10.1016/j.alit.2019.04.006
34. Coppola A, Flores KR, De Filippis F. Rapid onset of effect of benralizumab on respiratory symptoms in a patient with eosinophilic granulomatosis with polyangiitis. Respir Med Case Rep 2020; 30: 101050. https://doi. org/10.1016/j.rmcr.2020.101050
35. Kolios AGA, Lutterotti A, Kulcsar Z, Renner T, Rudiger A, Nilsson J. Benralizumab in eosinophilic granulomatosis with polyangiitis complicated by Staphylococcus aureus sepsis. Clinical Immunology 2021; 222: 108574. https:// doi.org/10.1016/j.clim.2020.108574
36. Kent BD, d’Ancona G, Fernandes M, Green L, Roxas C, Thomson L, et al. Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. ERJ Open Res 2020; 6(1): 00311- 2019. https://doi.org/10.1183/23120541.00311-2019
37. Manka LA, Guntur VP, Denson JL, Dunn RM, Dollin YT, Strand MJ, et al. Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. Ann Allergy Asthma Immunol 2021; 126(6): 696-701.e1. https://doi.org/10.1016/j.anai.2021.01.035
38. Jachiet M, Samson M, Cottin V, Kahn JE, Le Guenno G, Bonniaud P, et al. Anti-IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss): data on seventeen patients. Arthritis Rheumatol 2016; 68: 2274e82. https://doi.org/10.1002/art.39663
39. Celebi Sozener Z, Gorgulu B, Mungan D, Sin BA, Misirligil Z, Aydin O, et al. Omalizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA): single-center experience in 18 cases. World Allergy Organ J 2018; 11:39. https://doi.org/10.1186/s40413-018-0217-0
40. Mohammad AJ, Hot A, Arndt F, Moosig F, Guerry MJ, Amudala N, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg–Strauss). Ann Rheum Dis 2016; 75: 396-401. https://doi. org/10.1136/annrheumdis-2014-206095

APA	Bayrak Durmaz M, ÇELEBI SOZENER Z, Bavbek S (2022). Eosinophilic granulomatosis with polyangitis: A new target for biologicals. , 93 - 101. 10.5578/tt.20229911
Chicago	Bayrak Durmaz Makbule Seda,ÇELEBI SOZENER ZEYNEP,Bavbek Sevim Eosinophilic granulomatosis with polyangitis: A new target for biologicals. (2022): 93 - 101. 10.5578/tt.20229911
MLA	Bayrak Durmaz Makbule Seda,ÇELEBI SOZENER ZEYNEP,Bavbek Sevim Eosinophilic granulomatosis with polyangitis: A new target for biologicals. , 2022, ss.93 - 101. 10.5578/tt.20229911
AMA	Bayrak Durmaz M,ÇELEBI SOZENER Z,Bavbek S Eosinophilic granulomatosis with polyangitis: A new target for biologicals. . 2022; 93 - 101. 10.5578/tt.20229911
Vancouver	Bayrak Durmaz M,ÇELEBI SOZENER Z,Bavbek S Eosinophilic granulomatosis with polyangitis: A new target for biologicals. . 2022; 93 - 101. 10.5578/tt.20229911
IEEE	Bayrak Durmaz M,ÇELEBI SOZENER Z,Bavbek S "Eosinophilic granulomatosis with polyangitis: A new target for biologicals." , ss.93 - 101, 2022. 10.5578/tt.20229911
ISNAD	Bayrak Durmaz, Makbule Seda vd. "Eosinophilic granulomatosis with polyangitis: A new target for biologicals". (2022), 93-101. https://doi.org/10.5578/tt.20229911

APA	Bayrak Durmaz M, ÇELEBI SOZENER Z, Bavbek S (2022). Eosinophilic granulomatosis with polyangitis: A new target for biologicals. Tüberküloz ve Toraks, 70(1), 93 - 101. 10.5578/tt.20229911
Chicago	Bayrak Durmaz Makbule Seda,ÇELEBI SOZENER ZEYNEP,Bavbek Sevim Eosinophilic granulomatosis with polyangitis: A new target for biologicals. Tüberküloz ve Toraks 70, no.1 (2022): 93 - 101. 10.5578/tt.20229911
MLA	Bayrak Durmaz Makbule Seda,ÇELEBI SOZENER ZEYNEP,Bavbek Sevim Eosinophilic granulomatosis with polyangitis: A new target for biologicals. Tüberküloz ve Toraks, vol.70, no.1, 2022, ss.93 - 101. 10.5578/tt.20229911
AMA	Bayrak Durmaz M,ÇELEBI SOZENER Z,Bavbek S Eosinophilic granulomatosis with polyangitis: A new target for biologicals. Tüberküloz ve Toraks. 2022; 70(1): 93 - 101. 10.5578/tt.20229911
Vancouver	Bayrak Durmaz M,ÇELEBI SOZENER Z,Bavbek S Eosinophilic granulomatosis with polyangitis: A new target for biologicals. Tüberküloz ve Toraks. 2022; 70(1): 93 - 101. 10.5578/tt.20229911
IEEE	Bayrak Durmaz M,ÇELEBI SOZENER Z,Bavbek S "Eosinophilic granulomatosis with polyangitis: A new target for biologicals." Tüberküloz ve Toraks, 70, ss.93 - 101, 2022. 10.5578/tt.20229911
ISNAD	Bayrak Durmaz, Makbule Seda vd. "Eosinophilic granulomatosis with polyangitis: A new target for biologicals". Tüberküloz ve Toraks 70/1 (2022), 93-101. https://doi.org/10.5578/tt.20229911